68 related articles for article (PubMed ID: 10368634)
21. Multiple mitogenic pathways in pancreatic cancer cells are blocked by a truncated epidermal growth factor receptor.
Matsuda K; Idezawa T; You XJ; Kothari NH; Fan H; Korc M
Cancer Res; 2002 Oct; 62(19):5611-7. PubMed ID: 12359775
[TBL] [Abstract][Full Text] [Related]
22. Blockade of epidermal growth factor receptor signaling leads to inhibition of renal cell carcinoma growth in the bone of nude mice.
Weber KL; Doucet M; Price JE; Baker C; Kim SJ; Fidler IJ
Cancer Res; 2003 Jun; 63(11):2940-7. PubMed ID: 12782601
[TBL] [Abstract][Full Text] [Related]
23. Structure-based design of potent inhibitors of EGF-receptor tyrosine kinase as anti-cancer agents.
Ghosh S; Narla RK; Zheng Y; Liu XP; Jun X; Mao C; Sudbeck EA; Uckun FM
Anticancer Drug Des; 1999 Oct; 14(5):403-10. PubMed ID: 10766295
[TBL] [Abstract][Full Text] [Related]
24. Involvement of hepatocyte epidermal growth factor receptor mediated activation of mitogen-activated protein kinase signaling pathways in response to growth inhibition by a novel K vitamin.
Wang Z; Wang M; Carr BI
J Cell Physiol; 2000 Jun; 183(3):338-46. PubMed ID: 10797308
[TBL] [Abstract][Full Text] [Related]
25. Epidermal growth factor receptor tyrosine kinase inhibitor does not improve paclitaxel effect in an orthotopic mouse model of lung cancer.
Onn A; Isobe T; Wu W; Itasaka S; Shintani T; Shibuya K; Kenji Y; O'reilly MS; Fidler IJ; Herbst RS
Clin Cancer Res; 2004 Dec; 10(24):8613-9. PubMed ID: 15623645
[TBL] [Abstract][Full Text] [Related]
26. Differential responses of EGFR-/AGT-expressing cells to the "combi-triazene" SMA41.
Matheson SL; McNamee JP; Jean-Claude BJ
Cancer Chemother Pharmacol; 2003 Jan; 51(1):11-20. PubMed ID: 12497201
[TBL] [Abstract][Full Text] [Related]
27. High levels of HER-2 expression alter the ability of epidermal growth factor receptor (EGFR) family tyrosine kinase inhibitors to inhibit EGFR phosphorylation in vivo.
Christensen JG; Schreck RE; Chan E; Wang X; Yang C; Liu L; Cui J; Sun L; Wei J; Cherrington JM; Mendel DB
Clin Cancer Res; 2001 Dec; 7(12):4230-8. PubMed ID: 11751524
[TBL] [Abstract][Full Text] [Related]
28. Tyrosine kinase inhibitors. 12. Synthesis and structure-activity relationships for 6-substituted 4-(phenylamino)pyrimido[5,4-d]pyrimidines designed as inhibitors of the epidermal growth factor receptor.
Rewcastle GW; Bridges AJ; Fry DW; Rubin JR; Denny WA
J Med Chem; 1997 Jun; 40(12):1820-6. PubMed ID: 9191958
[TBL] [Abstract][Full Text] [Related]
29. Identification of the amyloid β-protein precursor and cystatin C as novel epidermal growth factor receptor regulated secretory proteins in nasopharyngeal carcinoma by proteomics.
Tang CE; Guan YJ; Yi B; Li XH; Liang K; Zou HY; Yi H; Li MY; Zhang PF; Li C; Peng F; Chen ZC; Yao KT; Xiao ZQ
J Proteome Res; 2010 Dec; 9(12):6101-11. PubMed ID: 20882990
[TBL] [Abstract][Full Text] [Related]
30. Tyrosine kinase inhibitors. 10. Isomeric 4-[(3-bromophenyl)amino]pyrido[d]-pyrimidines are potent ATP binding site inhibitors of the tyrosine kinase function of the epidermal growth factor receptor.
Rewcastle GW; Palmer BD; Thompson AM; Bridges AJ; Cody DR; Zhou H; Fry DW; McMichael A; Denny WA
J Med Chem; 1996 Apr; 39(9):1823-35. PubMed ID: 8627606
[TBL] [Abstract][Full Text] [Related]
31. Tyrphostins. 6. Dimeric benzylidenemalononitrile tyrophostins: potent inhibitors of EGF receptor tyrosine kinase in vitro.
Gazit A; Osherov N; Gilon C; Levitzki A
J Med Chem; 1996 Dec; 39(25):4905-11. PubMed ID: 8960549
[TBL] [Abstract][Full Text] [Related]
32. Antitumor effect and enhancement of cytotoxic drug activity by cetuximab in nasopharyngeal carcinoma cells.
Sung FL; Poon TC; Hui EP; Ma BB; Liong E; To KF; Huang DP; Chan AT
In Vivo; 2005; 19(1):237-45. PubMed ID: 15796181
[TBL] [Abstract][Full Text] [Related]
33. [Effect of epidermal growth factor receptor-selective tyrosine kinase inhibitor gefitinib on nasopharyngeal carcinoma xenografts].
Wang SS; Guan ZZ; Xiang YQ; Jiang WQ; Lin TY; Zhang L
Ai Zheng; 2004 Nov; 23(11 Suppl):1365-9. PubMed ID: 15566638
[TBL] [Abstract][Full Text] [Related]
34. Developmental changes in neural progenitor cell lineage commitment do not depend on epidermal growth factor receptor signaling.
Zhu G; Mehler MF; Mabie PC; Kessler JA
J Neurosci Res; 2000 Feb; 59(3):312-20. PubMed ID: 10679766
[TBL] [Abstract][Full Text] [Related]
35. A high-throughput soft agar assay for identification of anticancer compound.
Anderson SN; Towne DL; Burns DJ; Warrior U
J Biomol Screen; 2007 Oct; 12(7):938-45. PubMed ID: 17942786
[TBL] [Abstract][Full Text] [Related]
36. A cell and mechanism-based approach for the selection of EGF receptor inhibitors.
Lanzi C; Pensa T; Cassinis M; Corti C; Gambetta RA; Pratesi G; Menta E; Ardini E; Zunino F
Anticancer Drug Des; 1997 Sep; 12(6):515-24. PubMed ID: 9311559
[No Abstract] [Full Text] [Related]
37. The epidermal growth factor receptor is not required for tumor necrosis factor-alpha action in normal mammary epithelial cells.
Varela LM; Darcy KM; Ip MM
Endocrinology; 1997 Sep; 138(9):3891-900. PubMed ID: 9275079
[TBL] [Abstract][Full Text] [Related]
38. Anti-EGFR therapies in nasopharyngeal carcinoma.
Chen X; Liang R; Zhu X
Biomed Pharmacother; 2020 Nov; 131():110649. PubMed ID: 32836074
[TBL] [Abstract][Full Text] [Related]
39. Novel systemic therapeutic for nasopharyngeal carcinoma.
Chan SL; Ma BB
Expert Opin Ther Targets; 2012 Mar; 16 Suppl 1():S63-8. PubMed ID: 22313344
[TBL] [Abstract][Full Text] [Related]
40. Immunohistochemical determination of EGFR-tyrosine kinase inhibition in clinical samples.
Malik SN; Bedolla RG; Hidalgo M; Brattain MG; Kreisberg JI
Methods Mol Med; 2003; 85():135-40. PubMed ID: 12710204
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
